MedTrace Logo

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

NCT03649321 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-11-09

Study results available
· View outcomes & findings →

Summary

Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.

Conditions

  • Cancer of Pancreas

Interventions

DRUG

Bemcentinib

200mg orally starting Cycle 1 day 2 every 21 days or 28 days.

DRUG

Nab-paclitaxel

25 mg/m\^2 Day 1 /8 every 21 days or 28 days.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days

DRUG

Cisplatin

Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days

Sponsors & Collaborators

  • Triligent International

    collaborator INDUSTRY

  • Translational Genomics Research Institute

    collaborator OTHER

  • BerGenBio ASA

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Syed Kazmi, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2022-06-27
Completion
2022-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649321 on ClinicalTrials.gov